Active Surveillance Monitoring More Stringent in Updated NCCN Guidelines for Prostate Cancer
Tightened monitoring for active surveillance and new systemic therapy recommendations for castration-recurrent metastatic prostate cancer were highlighted as notable updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Prostate Cancer at the National Comprehensive Cancer Network® (NCCN®) 16th Annual Conference.
HOLLYWOOD, FL — Active surveillance or immediate treatment? The question that many men with prostate cancer and their clinicians struggle with continues to be a focus in the updated NCCN Guidelines™ for Prostate Cancer. James L. Mohler, MD, of Roswell Park Cancer Institute and chair of the NCCN Guidelines Panel for Prostate Cancer, discussed more rigorous monitoring of men undergoing active surveillance and new treatment options for advanced prostate cancer in the recently updated NCCN Guidelines during a presentation at the NCCN 16th Annual Conference.
Active surveillance, also referred to as watchful waiting, is a viable option for many men with low-risk prostate cancer although the concept continues to cause distress and confusion for many men, especially when they read about the controversies associated with the use of prostate-specific antigen (PSA) for the early detection of prostate cancer, noted Dr. Mohler.
“The NCCN Guidelines Panel remains concerned about over-diagnosis and over-treatment of prostate cancer as growing evidence suggests that over-treatment of prostate cancer commits too many men to side effects that outweigh a very small risk of prostate cancer death,” stated Dr. Mohler.
Dr. Mohler discussed various organizations’ prostate cancer screening recommendations, including those by the American Cancer Society and American Urological Association as well as the NCCN Guidelines for Early Detection of Prostate Cancer.
“The current NCCN Guidelines recommend that at age 40, high-risk men begin annual PSA and prostate exams. All other men at age 40 should be offered a baseline PSA and prostate exams and, if their PSA is 1.0 ng/mL or greater, they should receive annual follow-ups. If their PSA is less than 1.0, the NCCN Guidelines recommend that these men be early detected again at age 45,” said Dr. Mohler.
Dr. Mohler noted that the screening debate exploded in early 2009 as a result of the ERSPC (European) and the PLCO (American) studies published in the New England Journal of Medicine that led to media reports stating that PSA screening has little impact on the risk of death from the disease.
However, the 40 percent reduction in prostate cancer mortality in the United States since 1992 may be due to use of PSA. Results published recently from a Swedish population-based trial that was part of the larger ERSPC study, the Göteborg Study, suggested that PSA screening for prostate cancer reduced prostate cancer-specific mortality by approximately 50 percent, a rate similar to the overall reduction that has occurred in the United States.
In 2010, the NCCN Guidelines established a new “very low risk” category that incorporated the strictest Epstein criteria from all definitions for clinically insignificant prostate cancer and recommended active surveillance as the sole initial treatment for men who meet these criteria and have a life expectancy of more than 20 years. Men with low risk prostate cancer and a life expectancy of less than 10 years should also be recommended for active surveillance.
In the updated 2011 NCCN Guidelines, active surveillance monitoring was made more rigorous for men in the very low risk category. For those with a life expectancy of less than 20 years, PSA must be measured at least every 6 months, prostate exam must be performed at least every 12 months, and repeat prostate biopsies should be considered as often as every 12 months.
Dr. Mohler noted that there are several conundrums related to active surveillance that complicate the issue further, including overtreatment rates, clinical risks associated with prostate biopsies, and differing criteria for active surveillance and disease progression in large clinical series, all of which need to be taken into consideration when making treatment decisions.
“Ultimately, this decision must be based on careful individualized weighting of a number of factors and is an option that needs to be thoroughly discussed with the patient and all of his physicians. Clearly, more clinical research is necessary to better inform decision-making,” said Dr. Mohler.
Another significant update to the NCCN Guidelines includes the addition of sipuleucel-T (PROVENGE®, Dendreon Corporation) as an immunotherapy option for asymptomatic or minimally symptomatic castration-recurrent metastatic prostate cancer. A recent clinical trial showed that sipuleucel-T extends the median survival of men with advanced prostate cancer who were treated with the drug.
“The NCCN Guidelines have been modified to include sipuleucel-T as a category 1 recommendation that is appropriate as salvage treatment for patients with castration-recurrent prostate cancer who have minimally symptomatic disease, an ECOG performance score of 0 or 1, and a life expectancy of at least 6 months,” noted Dr. Mohler.
The updated NCCN Guidelines also include cabazitaxel (JEVTANA®, sanofi-aventis) as a new second-line option for men with castration-recurrent metastatic prostate cancer who fail docetaxel (Taxotere®, sanofi-aventis). The recommendation was added following a clinical trial showing a 30 percent risk reduction of death for those treated with cabazitaxel compared to mitoxantrone (Novantrone®, OSI Oncology).
“The addition of both of these therapies into the NCCN Guidelines represents a significant advancement in the care of men with advanced prostate cancer,” said Dr. Mohler.
Lastly, denosumab (XGEVA™, Amgen) has been added to the NCCN Guidelines as an alternative to zoledronic acid (Zometa®, Novartis Oncology) for the prevention of skeletal-related events.
“In men with castration-recurrent prostate cancer who have bone metastases, denosumab was shown superior to zoledronic acid in preventing disease-related skeletal complications, which include fracture, spinal cord compression, or the need for surgery or radiation therapy to bone,” said Dr. Mohler.
However, he noted that the choice of which agent to use should depend upon several variables, including under-lying co-morbidities and whether the patient has been treated with zoledronic acid previously.
The NCCN Guidelines are developed and updated through an evidence-based process with explicit review of the scientific evidence integrated with expert judgment by multidisciplinary panels of expert physicians from NCCN Member Institutions. The most recent version of this and all the NCCN Guidelines are available free of charge at NCCN.org. NCCN Guidelines for Patients™: Prostate Cancer is now available on-line at NCCN.com.
About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 26 of the world's leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives. For more information, visit NCCN.org.
The NCCN Member Institutions are:
- Fred & Pamela Buffett Cancer Center
- Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute
- City of Hope Comprehensive Cancer Center
- Dana-Farber/Brigham and Women's Cancer Center
Massachusetts General Hospital Cancer Center
- Duke Cancer Institute
- Fox Chase Cancer Center
- Huntsman Cancer Institute at the University of Utah
- Fred Hutchinson Cancer Research Center / Seattle Cancer Care Alliance
- The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University
- Mayo Clinic Cancer Center
- Memorial Sloan Kettering Cancer Center
- Moffitt Cancer Center
- The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
- Roswell Park Cancer Institute
- Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
- St. Jude Children's Research Hospital/The University of Tennessee Health Science Center
- Stanford Cancer Institute
- University of Alabama at Birmingham Comprehensive Cancer Center
- UC San Diego Moores Cancer Center
- UCSF Helen Diller Family Comprehensive Cancer Center
- University of Colorado Cancer Center
- University of Michigan Comprehensive Cancer Center
- The University of Texas MD Anderson Cancer Center
- Vanderbilt-Ingram Cancer Center
- Yale Cancer Center/Smilow Cancer Hospital